Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
AstraZeneca
Seagen Inc.
Genmab
Seagen Inc.
Exelixis
Mayo Clinic
University of Kentucky
Kivu Bioscience Inc.
EpiBiologics
AstraZeneca
STORM Therapeutics LTD
Neonc Technologies, Inc.
Arcus Biosciences, Inc.
Sumitomo Pharma America, Inc.
Bristol-Myers Squibb
Radiopharm Theranostics, Ltd
Seagen Inc.
Bayer
Pfizer
Pfizer
Radiopharm Theranostics, Ltd
Pfizer
Tizona Therapeutics, Inc
Boehringer Ingelheim
Aulos Bioscience, Inc.
Novartis
ALX Oncology Inc.
Clasp Therapeutics, Inc.
Exscientia AI Limited
OHSU Knight Cancer Institute
Eli Lilly and Company
Poseida Therapeutics, Inc.
MacroGenics
Baylor College of Medicine
DualityBio Inc.
MacroGenics
Amgen
University of California, Davis
SystImmune Inc.
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
One-carbon Therapeutics AB
Boundless Bio, Inc.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Seagen Inc.
Eli Lilly and Company
Qilu Pharmaceutical Co., Ltd.
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Pfizer